ORION Corp. (KRX:271560)

South Korea flag South Korea · Delayed Price · Currency is KRW
131,600
+3,600 (2.81%)
Last updated: Jun 9, 2026, 2:35 PM KST
Market Cap5.06T +3.7%
Revenue (ttm)3.46T +9.6%
Net Income402.86B -24.7%
EPS10,191.70 -24.7%
Shares Out 39.53M
PE Ratio12.56
Forward PE10.33
Dividend2,500.00 (1.89%)
Ex-Dividend DateMar 30, 2026
Volume63,166
Open128,000
Previous Close128,000
Day's Range126,600 - 131,900
52-Week Range99,000 - 150,100
Beta0.28
AnalystsBuy
Price Target162,135.29 (+23.2%)
Earnings DateAug 14, 2026

About ORION

ORION Corp., together with its subsidiaries, engages in the manufacture and sale of various confectionery products in South Korea, China, and internationally. It offers pies, snacks, biscuits, candies, gums, and chocolates; protein drinks/powders and bars/balls bars; bar and oat products; and mineral water under the Dr.You, Market O, Market O Nature, and Jeju yongamsoo brands. The company also produces and distributes films; and provides in vitro diagnostics for early detection of cancer and vaccines for contagious diseases. In addition, it man... [Read more]

Industry Confectioners
Founded 1956
Employees 1,471
Stock Exchange Korea Stock Exchange
Ticker Symbol 271560
Full Company Profile

Financial Performance

In 2025, ORION's revenue was 3.33 trillion, an increase of 7.35% compared to the previous year's 3.10 trillion. Earnings were 382.71 billion, a decrease of -27.05%.

Financial Statements

Analyst Summary

According to 17 analysts, the average rating for 271560 stock is "Buy." The 12-month stock price target is ₩162,135, which is an increase of 23.20% from the latest price.

Price Target
₩162,135
(23.20% upside)
Analyst Consensus: Buy
Stock Forecasts

News

Orion Corporation's financial reporting and Annual General Meeting in 2026

ORION CORPORATION STOCK EXCHANGE RELEASE – FINANCIAL CALENDAR 18 JULY 2025 at 9.30 EEST Orion Corporation's financial reporting and Annual General Meeting in 2026 Orion Corporation will publish its Fi...

11 months ago - Benzinga

Shilpa Medicare subsidiary partners with Orion Corporation to commercialize Recombinant Human Albumin in Europe

Shilpa Medicare Limited has announced that its wholly owned subsidiary, Shilpa Biocare Private Limited, has entered into a strategic agreement with Orion Corporation, a pharmaceutical company based in...

1 year ago - Business Upturn